8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Feb 2, 2026·SEC
DarioHealth Corp.(DRIO)Earnings, Financials & Key Ratios
DRIO•NASDAQ
5.6× P/E·Price updated Jun 19, 2026
AboutDarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Show more
- Revenue$22M-17.3%
- EBITDA-$33M+34.2%
- Net Income-$42M+2.4%
- EPS (Diluted)1.24+267.6%
- Gross Margin56.64%+15.4%
- EBITDA Margin-148.02%+20.5%
- Operating Margin-163.94%+23.2%
- Net Margin-186.56%-18.0%
- ROE-59.62%+9.2%
DRIO Key Insights
DarioHealth Corp. (DRIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 24.2%
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Shares diluted 22.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DRIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DRIO Price & Volume
DarioHealth Corp. (DRIO) stock price & volume — 10-year historical chart
Loading chart...
DRIO Growth Metrics
DarioHealth Corp. (DRIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.13%
5 Years24.17%
3 Years-6.84%
TTM-24.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM239.99%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1347.88%
Return on Capital
10 Years-198.13%
5 Years-70.73%
3 Years-53.11%
Last Year-36.11%
DRIO Recent Earnings
DarioHealth Corp. (DRIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.81+25.7%
$1.09
Rev
$6M+2.3%
$5M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.80+67.2%
$2.44
Rev
$5M+3.0%
$5M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.85+29.7%
$2.63
Rev
$5M-0.8%
$5M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$2.40-9.1%
$2.20
Rev
$5M-24.2%
$7M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.81vs $1.09+25.7% | $6Mvs $5M+2.3% |
| Q2 2026 | Mar 19, 2026 | $0.80vs $2.44+67.2% | $5Mvs $5M+3.0% |
| Q4 2025 | Nov 13, 2025 | $1.85vs $2.63+29.7% | $5Mvs $5M-0.8% |
| Q3 2025 | Aug 12, 2025 | $2.40vs $2.20-9.1% | $5Mvs $7M-24.2% |
Based on last 12 quarters of dataView full earnings history →
DRIO Peer Comparison
DarioHealth Corp. (DRIO) competitors in Point-of-Care and Rapid Testing — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TDOC | 1.46B | 8.07 | -7.08 | -1.54% | -6.81% | -12.37% | 0.75 | |
 OMCL | 1.78B | 39.05 | 881.49 | 6.53% | 1.67% | 1.64% | 0.17 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 DXCM | 27.96B | 72.47 | 34.67 | 15.6% | 19.31% | 33.83% | 0.51 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 PODD | 10.23B | 145.76 | 41.89 | 30.73% | 10.44% | 21.38% | 0.69 | |
 TNDM | 1.05B | 15.30 | -5.03 | 7.93% | -9.2% | -68.29% | 2.86 |
Compare DRIO vs Peers
DarioHealth Corp. (DRIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DRIO Income Statement
DarioHealth Corp. (DRIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 5.17M | 7.39M | 7.56M | 7.58M | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M | 21.19M |
Revenue Growth % | 84.45% | 43.02% | 2.23% | 0.22% | 170.76% | 34.82% | -26.41% | 32.86% | -17.31% | -24.41% |
Cost of Goods Sold | 3.86M | 5.63M | 4.96M | 5.06M | 12.44M | 18M | 14.37M | 13.77M | 9.69M | 9.21M |
COGS % of Revenue | 74.64% | 76.13% | 65.64% | 66.83% | 60.66% | 65.09% | 70.6% | 50.94% | 43.36% | - |
Gross Profit | 1.31M▲ 0% | 1.76M▲ 34.6% | 2.6M▲ 47.1% | 2.51M▼ 3.2% | 8.07M▲ 221.1% | 9.65M▲ 19.7% | 5.98M▼ 38.0% | 13.27M▲ 121.7% | 12.66M▼ 4.5% | 11.98M▲ 0% |
Gross Margin % | 25.36% | 23.87% | 34.36% | 33.17% | 39.34% | 34.91% | 29.4% | 49.06% | 56.64% | 56.55% |
Gross Profit Growth % | 333.69% | 34.63% | 47.14% | -3.23% | 221.09% | 19.66% | -38.02% | 121.71% | -4.54% | - |
Operating Expenses | 15.73M | 19.45M | 20.3M | 32.42M | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M | 65.36M |
OpEx % of Revenue | 304.26% | 263.09% | 268.58% | 427.88% | 412.24% | 240.33% | 305.49% | 262.61% | 220.58% | - |
Selling, General & Admin | 12.43M | 15.78M | 16.61M | 27.98M | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M | 34.47M |
SG&A % of Revenue | 240.48% | 213.38% | 219.74% | 369.36% | 303.99% | 169.28% | 205.37% | 173.2% | 158.9% | - |
Research & Development | 3.3M | 3.68M | 3.69M | 4.43M | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M | 12.07M |
R&D % of Revenue | 63.77% | 49.72% | 48.84% | 58.51% | 83.94% | 71.05% | 99.49% | 89.42% | 61.68% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 4.99M | 0 | 128K | 0 | 0 | 0 |
Operating Income | -14.42M▲ 0% | -17.69M▼ 22.7% | -17.7M▼ 0.1% | -29.9M▼ 68.9% | -76.49M▼ 155.8% | -56.81M▲ 25.7% | -56.19M▲ 1.1% | -57.74M▼ 2.8% | -36.66M▲ 36.5% | -53.37M▲ 0% |
Operating Margin % | -278.9% | -239.22% | -234.22% | -394.71% | -372.9% | -205.42% | -276.09% | -213.55% | -163.94% | -251.87% |
Operating Income Growth % | -29.89% | -22.67% | -0.1% | -68.9% | -155.81% | 25.73% | 1.09% | -2.77% | 36.52% | - |
EBITDA | -14.22M | -17.48M | -17.52M | -29.71M | -72.04M | -52.09M | -51.2M | -50.32M | -33.1M | -53.99M |
EBITDA Margin % | -275.13% | -236.42% | -231.8% | -392.2% | -351.18% | -188.36% | -251.59% | -186.08% | -148.02% | -254.8% |
EBITDA Growth % | -32.76% | -22.9% | -0.23% | -69.58% | -142.44% | 27.69% | 1.71% | 1.73% | 34.23% | -195.3% |
D&A (Non-Cash Add-back) | 195K | 207K | 183K | 190K | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M | -622K |
EBIT | -14.42M | -17.69M | -17.7M | -29.9M | -74.47M | -60.31M | -59.36M | -57.74M | -36.66M | -34.55M |
Net Interest Income | -171K | -18K | -11K | 12K | -40K | -2.18M | 1.22M | 1.02M | -2.42M | -3.68M |
Interest Income | 0 | 0 | 16K | 61K | 44K | 506K | 1.87M | 1.12M | 943K | 814K |
Interest Expense | 171K | 18K | 27K | 49K | 84K | 2.68M | 645K | 96K | 3.36M | 4.5M |
Other Income/Expense | -1.32M | -115K | -31K | 458K | -235K | -5.38M | -3.17M | 13.14M | -4.95M | 116.12M |
Pretax Income | -15.74M▲ 0% | -17.8M▼ 13.1% | -17.74M▲ 0.4% | -29.45M▼ 66.0% | -76.73M▼ 160.6% | -62.19M▲ 18.9% | -59.36M▲ 4.5% | -44.6M▲ 24.9% | -41.61M▲ 6.7% | 62.75M▲ 0% |
Pretax Margin % | -304.51% | -240.78% | -234.63% | -388.66% | -374.05% | -224.87% | -291.68% | -164.94% | -186.1% | 296.11% |
Income Tax | 0 | -115K | 0 | 0 | 32K | 4K | 64K | -1.85M | 105K | 35K |
Effective Tax Rate % | 0% | 0.65% | 0% | 0% | -0.04% | -0.01% | -0.11% | 4.15% | -0.25% | 0.06% |
Net Income | -15.74M▲ 0% | -17.8M▼ 13.1% | -17.74M▲ 0.4% | -29.45M▼ 66.0% | -76.76M▼ 160.7% | -62.19M▲ 19.0% | -59.43M▲ 4.4% | -42.75M▲ 28.1% | -41.71M▲ 2.4% | 62.71M▲ 0% |
Net Margin % | -304.51% | -240.78% | -234.63% | -388.66% | -374.21% | -224.88% | -292% | -158.09% | -186.56% | 295.94% |
Net Income Growth % | -44.6% | -13.09% | 0.38% | -66.02% | -160.69% | 18.98% | 4.45% | 28.07% | 2.42% | 239.99% |
Net Income (Continuing) | -15.74M | -17.8M | -17.74M | -29.45M | -76.76M | -62.19M | -59.43M | -42.75M | -41.71M | 62.71M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -32.70▲ 0% | -15.21▲ 53.5% | -7.84▲ 48.5% | -5.55▲ 29.2% | -4.63▲ 16.6% | -2.63▲ 43.2% | -1.93▲ 26.6% | -0.74▲ 61.7% | 1.24▲ 267.6% | 1.26▲ 0% |
EPS Growth % | 21.86% | 53.49% | 48.45% | 29.21% | 16.58% | 43.2% | 26.62% | 61.66% | 267.57% | 1347.88% |
EPS (Basic) | -32.70 | -15.21 | -7.84 | -5.55 | -4.63 | -2.63 | -1.93 | -0.74 | 1.24 | - |
Diluted Shares Outstanding | 481.41K | 1.17M | 2.27M | 5.96M | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M | 49.63M |
Basic Shares Outstanding | 481.41K | 1.17M | 2.27M | 5.96M | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M | 49.63M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DRIO Balance Sheet
DarioHealth Corp. (DRIO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6.05M | 13.31M | 22.91M | 34.13M | 45.6M | 65.52M | 47.33M | 40.53M | 34.81M | 28.47M |
Cash & Short-Term Investments | 3.98M | 11M | 20.59M | 28.59M | 36M | 49.36M | 36.8M | 28.46M | 26.25M | 20.26M |
Cash Only | 3.72M | 11M | 20.59M | 28.59M | 36M | 49.36M | 36.8M | 27.76M | 26.25M | 20.26M |
Short-Term Investments | 258K | 0 | 0 | 0 | 0 | 0 | 0 | 697K | 0 | 0 |
Accounts Receivable | 435K | 234K | 712K | 1.7M | 1.79M | 6.42M | 3.64M | 5.35M | 2.67M | 2.22M |
Days Sales Outstanding | 30.71 | 11.55 | 34.38 | 82.1 | 31.78 | 84.68 | 65.33 | 72.24 | 43.6 | 54.49 |
Inventory | 1.18M | 1.38M | 1.41M | 2.29M | 6.23M | 7.96M | 5.06M | 4.75M | 4.32M | 4.17M |
Days Inventory Outstanding | 111.99 | 89.29 | 104.01 | 165.31 | 182.68 | 161.32 | 128.59 | 125.96 | 162.51 | 178.04 |
Other Current Assets | 258K | 251K | 0 | 187K | 0 | 887K | 292K | 175K | 0 | 1.81M |
Total Non-Current Assets | 911K | 776K | 1.65M | 1.28M | 55.17M | 53.67M | 49.06M | 78.36M | 75.27M | 74.81M |
Property, Plant & Equipment | 869K | 733K | 1.41M | 1.07M | 989K | 1.99M | 1.87M | 1.77M | 0 | 1.12M |
Fixed Asset Turnover | 5.95x | 10.09x | 5.35x | 7.05x | 20.74x | 13.87x | 10.91x | 15.24x | - | 21.66x |
Goodwill | 0 | 0 | 0 | 0 | 41.64M | 41.64M | 41.64M | 57.43M | 57.43M | 57.43M |
Intangible Assets | 0 | 0 | 0 | 0 | 12.46M | 9.92M | 5.4M | 18.76M | 15.93M | 15.47M |
Long-Term Investments | 42K | 43K | 17K | 0 | 20K | 6K | 6K | 0 | 80K | 239K |
Other Non-Current Assets | 0 | 0 | 224K | 205K | 57K | 117K | 143K | 392K | 1.83M | 720K |
Total Assets | 6.96M▲ 0% | 14.09M▲ 102.5% | 24.57M▲ 74.4% | 35.41M▲ 44.1% | 100.77M▲ 184.6% | 119.19M▲ 18.3% | 96.39M▼ 19.1% | 118.88M▲ 23.3% | 110.08M▼ 7.4% | 103.28M▲ 0% |
Asset Turnover | 0.74x | 0.52x | 0.31x | 0.21x | 0.20x | 0.23x | 0.21x | 0.23x | 0.20x | 0.19x |
Asset Growth % | 79.67% | 102.52% | 74.38% | 44.11% | 184.61% | 18.28% | -19.13% | 23.34% | -7.41% | -22.3% |
Total Current Liabilities | 3.02M | 5.16M | 5.22M | 7.03M | 14.38M | 19.35M | 12.49M | 16.64M | 9.32M | 9.36M |
Accounts Payable | 1.85M | 2.57M | 1.66M | 2.48M | 5.11M | 2.32M | 1.13M | 3.04M | 2.93M | 3.47M |
Days Payables Outstanding | 175.17 | 166.91 | 121.81 | 178.79 | 149.85 | 47.08 | 28.73 | 80.7 | 110.25 | 131.25 |
Short-Term Debt | 0 | 0 | 317K | 0 | 266K | 8.82M | 3.95M | 5.45M | 430K | 378K |
Deferred Revenue (Current) | 0 | 736K | 1.22M | 1.22M | 1.2M | 1.32M | 997K | 1.58M | 714K | 2.8M |
Other Current Liabilities | 0 | 880K | 887K | 880K | 4.4M | 2.19M | 4.07M | 0 | 5.25M | 5.01M |
Current Ratio | 2.01x | 2.58x | 4.39x | 4.85x | 3.17x | 3.39x | 3.79x | 2.44x | 3.73x | 3.04x |
Quick Ratio | 1.61x | 2.31x | 4.12x | 4.53x | 2.74x | 2.98x | 3.38x | 2.15x | 3.27x | 2.60x |
Cash Conversion Cycle | -32.47 | -66.07 | 16.58 | 68.61 | 64.6 | 198.92 | 165.2 | 117.51 | 95.86 | 101.28 |
Total Non-Current Liabilities | 1K | 0 | 455K | 222K | 846K | 19.84M | 25.75M | 30.23M | 32.83M | 31.54M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 18.11M | 24.59M | 23.47M | 30.75M | 30.93M |
Capital Lease Obligations | 0 | 0 | 455K | 222K | 21K | 827K | 885K | 765K | 571K | 2.27M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1K | 0 | 0 | 0 | 825K | 910K | 276K | 5.99M | 1.51M | 106K |
Total Liabilities | 3.02M | 5.16M | 5.67M | 7.26M | 15.22M | 39.19M | 38.24M | 46.87M | 42.15M | 40.9M |
Total Debt | 0 | 0 | 772K | 532K | 287K | 28.05M | 29.54M | 30.19M | 31.75M | 31.82M |
Net Debt | -3.72M | -11M | -19.81M | -28.06M | -35.71M | -21.31M | -7.26M | 2.43M | 5.5M | 11.55M |
Debt / Equity | - | - | 0.04x | 0.02x | 0.00x | 0.35x | 0.51x | 0.42x | 0.47x | 0.51x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.59x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.21x |
Interest Coverage | -84.32x | -982.67x | -655.74x | -610.27x | -886.60x | -22.48x | -92.04x | -601.50x | -10.91x | -7.68x |
Total Equity | 3.94M▲ 0% | 8.93M▲ 126.5% | 18.89M▲ 111.7% | 28.15M▲ 49.0% | 85.55M▲ 203.9% | 80M▼ 6.5% | 58.14M▼ 27.3% | 72.02M▲ 23.9% | 67.92M▼ 5.7% | 62.38M▲ 0% |
Equity Growth % | 160.25% | 126.47% | 111.7% | 48.99% | 203.89% | -6.49% | -27.32% | 23.86% | -5.69% | 1.04% |
Book Value per Share | 8.19 | 7.62 | 8.34 | 4.72 | 5.16 | 3.38 | 2.05 | 1.78 | 1.37 | 1.26 |
Total Shareholders' Equity | 3.94M | 8.93M | 18.89M | 28.15M | 85.55M | 80M | 58.14M | 72.02M | 67.92M | 62.38M |
Common Stock | 7K | 8K | 0 | 0 | 2K | 3K | 3K | 4K | 4K | 4K |
Retained Earnings | -70.96M | -89.25M | -110.14M | -143.25M | -222.01M | -285.85M | -349.36M | -390.34M | -452.08M | -460.33M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -477K | -440K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DRIO Cash Flow Statement
DarioHealth Corp. (DRIO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.62M | -11.47M | -15.72M | -17.74M | -50.41M | -47.84M | -30.38M | -38.56M | -25.94M | -25.29M |
Operating CF Margin % | -205.4% | -155.13% | -208.03% | -234.11% | -245.74% | -173% | -149.27% | -142.61% | -116.02% | - |
Operating CF Growth % | -26.73% | -8.01% | -37.1% | -12.79% | -184.22% | 5.09% | 36.51% | -26.94% | 32.73% | 69.28% |
Net Income | -15.74M | -17.8M | -17.74M | -29.45M | -76.76M | -62.19M | -59.43M | -42.75M | -41.71M | 62.71M |
Depreciation & Amortization | 195K | 207K | 183K | 457K | 4.46M | 4.72M | 4.99M | 7.43M | 2.83M | 2.04M |
Stock-Based Compensation | 3.82M | 3.76M | 2.26M | 11.1M | 24.97M | 16.98M | 19.7M | 15.8M | 9.37M | 5.51M |
Deferred Taxes | 0 | 0 | -4.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.18M | -1K | 4.69M | 0 | -503K | 3.56M | 288K | -16.57M | 1.37M | -1.51M |
Working Capital Changes | -77K | 2.37M | -429K | 150K | -2.57M | -10.9M | 4.07M | -2.47M | 2.21M | 1.01M |
Change in Receivables | -56K | 114K | -504K | -604K | -367K | -5.11M | 2.83M | 1.6M | 2.64M | 1.61M |
Change in Inventory | -295K | -193K | -37K | -879K | -2.23M | -1.73M | 2.89M | 308K | 437K | 451K |
Change in Payables | 39K | 722K | -918K | 824K | 1.08M | -2.79M | -1.19M | -496K | -122K | 713K |
Cash from Investing | -219K | 6K | -113K | -1.62M | -8.13M | -573K | -547K | -8.93M | -4.34M | -5.14M |
Capital Expenditures | -195K | -71K | -98K | -118K | -261K | -442K | -584K | -138K | -142K | -142K |
CapEx % of Revenue | 3.77% | 0.96% | 1.3% | 1.56% | 1.27% | 1.6% | 2.87% | 0.51% | 0.64% | 0.67% |
Acquisitions | 0 | 0 | 0 | 0 | -7.47M | 0 | 0 | -8.8M | 0 | 5K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -7K | -1K | 0 | -1.5M | -400K | -131K | 0 | 0 | 0 | 0 |
Cash from Financing | 13.46M | 18.74M | 25.25M | 27.55M | 65.77M | 61.94M | 18.25M | 38.53M | 24.31M | 17.5M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 23.79M | 1.77M | 0 | 185K | 0 |
Equity Issued (Net) | 13.46M | 18.74M | 25.25M | 27.55M | 64.88M | 38.15M | 16.48M | 38.53M | 24.13M | 17.31M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -134K | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 889K | 0 | 0 | 0 | 0 | 185K |
Net Change in Cash | 2.63M▲ 0% | 7.28M▲ 177.3% | 9.41M▲ 29.3% | 8.19M▼ 12.9% | 7.22M▼ 11.8% | 13.52M▲ 87.2% | -12.67M▼ 193.7% | -9.03M▲ 28.7% | -5.96M▲ 34.0% | -12.87M▲ 0% |
Free Cash Flow | -10.81M▲ 0% | -11.54M▼ 6.7% | -15.82M▼ 37.1% | -17.85M▼ 12.8% | -50.67M▼ 183.8% | -48.42M▲ 4.4% | -30.96M▲ 36.1% | -38.7M▼ 25.0% | -26.08M▲ 32.6% | -25.43M▲ 0% |
FCF Margin % | -209.17% | -156.09% | -209.33% | -235.67% | -247.01% | -175.07% | -152.14% | -143.12% | -116.66% | -120.03% |
FCF Growth % | -17.71% | -6.72% | -37.1% | -12.84% | -183.8% | 4.44% | 36.05% | -24.99% | 32.6% | 21.1% |
FCF per Share | -22.46 | -9.86 | -6.98 | -2.99 | -3.05 | -2.05 | -1.09 | -0.96 | -0.53 | -0.51 |
FCF Conversion (FCF/Net Income) | 0.67x | 0.64x | 0.89x | 0.60x | 0.66x | 0.77x | 0.51x | 0.90x | 0.62x | -0.41x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 1.88M | 4.03M | 3.93M | 0 | 313K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DRIO Key Ratios
DarioHealth Corp. (DRIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -399.47% | -276.74% | -127.51% | -125.18% | -135.02% | -75.14% | -86.04% | -65.68% | -59.62% | 93.18% |
Return on Invested Capital (ROIC) | - | - | - | - | -229.81% | -78.52% | -76.92% | -69.11% | -37.18% | -54.19% |
Gross Margin | 25.36% | 23.87% | 34.36% | 33.17% | 39.34% | 34.91% | 29.4% | 49.06% | 56.64% | 56.55% |
Net Margin | -304.51% | -240.78% | -234.63% | -388.66% | -374.21% | -224.88% | -292% | -158.09% | -186.56% | 295.94% |
Debt / Equity | - | - | 0.04x | 0.02x | 0.00x | 0.35x | 0.51x | 0.42x | 0.47x | 0.51x |
Interest Coverage | -84.32x | -982.67x | -655.74x | -610.27x | -886.60x | -22.48x | -92.04x | -601.50x | -10.91x | -7.68x |
FCF Conversion | 0.67x | 0.64x | 0.89x | 0.60x | 0.66x | 0.77x | 0.51x | 0.90x | 0.62x | -0.41x |
Revenue Growth | 84.45% | 43.02% | 2.23% | 0.22% | 170.76% | 34.82% | -26.41% | 32.86% | -17.31% | -24.41% |
Related:DRIO Dividend History·DRIO Revenue History·DRIO Price History·DRIO P/E History·DRIO Financial Ratios·DRIO Institutional Holders
DRIO SEC Filings & Documents
DarioHealth Corp. (DRIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
DRIO Frequently Asked Questions
DarioHealth Corp. (DRIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
DarioHealth Corp. (DRIO) reported $21.2M in revenue for fiscal year 2025.
DarioHealth Corp. (DRIO) saw revenue decline by 17.3% over the past year.
Yes, DarioHealth Corp. (DRIO) is profitable, generating $62.7M in net income for fiscal year 2025 (-186.6% net margin).
Dividend & Returns
DarioHealth Corp. (DRIO) has a return on equity (ROE) of -59.6%. Negative ROE indicates the company is unprofitable.
DarioHealth Corp. (DRIO) had negative free cash flow of $25.4M in fiscal year 2025, likely due to heavy capital investments.